Clinical Trial Update: Sacituzumab Govitecan Plus EV in Metastatic UC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating sacituzumab govitecan in combination with Enfortumab Vedotin for metastatic urothelial cancer; the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma
• Urothelial Carcinoma of the Renal Pelvis and Ureter

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Urothelial Cancer, Metastatic Urothelial Carcinoma | Phase 1, Phase 2 | Status: RECRUITING